Bio-Gene Technology Ltd
BGT
Company Profile
Business description
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene’s products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.
Contact
400 Collins Street
Level 6
MelbourneVIC3000
AUST: +61 390681062
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
Stocks News & Analysis
stocks
Big 4 earnings: Morningstar analysts form view on impact of slowing housing market
Big 4 bank maintains Fair Value, Short-term earnings not material enough to shift valuation for key player
stocks
ASX healthcare share remains cheap despite mixed earnings result
Shares in Aussie listed healthcare name undervalued post earnings.
stocks
Wide moat ASX share beats earnings guidance
Wide moat share continues to grow despite a challenging residential construction market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,397.30 | 8.20 | -0.09% |
| CAC 40 | 8,714.94 | 11.09 | -0.13% |
| DAX 40 | 26,391.42 | 67.54 | 0.26% |
| Dow JONES (US) | 53,791.85 | 184.13 | -0.34% |
| FTSE 100 | 10,844.19 | 18.31 | -0.17% |
| HKSE | 25,353.32 | 299.50 | -1.17% |
| NASDAQ | 26,445.45 | 159.91 | -0.60% |
| Nikkei 225 | 67,456.10 | 485.88 | 0.73% |
| NZX 50 Index | 13,737.66 | 123.00 | -0.89% |
| S&P 500 | 7,728.20 | 24.91 | -0.32% |
| S&P/ASX 200 | 9,202.70 | 8.90 | -0.10% |
| SSE Composite Index | 3,942.87 | 8.78 | 0.22% |